Pneomococcal Vaccine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
Conditions: Pneumococcal Infection Interventions: Biological: V116; Biological: PPSV23 Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

FDA Grants Priority Review to Merck ’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Acceptance based on results from multiple Phase 3 trials If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults The 21 serotypes covered by V116 are responsible for approximately 83% of invasive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 19, 2023 Category: Pharmaceuticals Source Type: clinical trials

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Conditions: Pneumococcal Vaccines Interventions: Biological: 31 valent pneumococcal conjugate vaccine; Biological: 20 valent pneumococcal conjugate vaccine Sponsors: Vaxcyte, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials

Merck ’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021 Results from Phase 3 trial, STRIDE-3, to be presented at World... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials

Pneumonia Vaccine Education Intervention Study
Conditions: Pneumonia, Pneumococcal; Vaccine Interventions: Behavioral: Pneumococcal Vaccine Education Sponsors: Geisinger Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
Conditions: Aging Interventions: Other: vaccine Sponsors: State University of New York at Buffalo; National Institute on Aging (NIA) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Conditions: Pneumococcal Vaccines Interventions: Biological: IVT PCV-25 Formulation A; Biological: IVT PCV-25 Formulation B; Biological: IVT PCV-25 Formulation C; Biological: PCV 20 Sponsors: Inventprise Inc.; Canadian Center for Vaccinology; Vaccine Evaluation Center, Canada; PATH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials

ACTIVATE in Public Housing
Conditions: Pneumonia; Influenza; Varicella Zoster; Meningitis; COVID-19; Vaccine Hesitancy Interventions: Behavioral: Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination Sponsors: Charles Drew University of Medicine and Science Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
Conditions: Diphtheria; Tetanus; Pertussis Interventions: Biological: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp); Biological: 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）; Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT) Sponsor: CanSino Biologics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)
Conditions: Diphtheria; Tetanus; Pertussis Interventions: Biological: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp); Biological: 23-Valent Pneumococcal Polysaccharide Vaccine （PPV23）; Biological: Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT) Sponsors: CanSino Biologics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
Condition: Pneumococcal Disease Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: control pneumococcal polysaccharide vaccine Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Condition: Lymphoma Intervention: Biological: PCV20 Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials